Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mapkure LLC is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, including BREDEFELD, RACHAEL EVA. As the busiest examiner for the portfolio, BREDEFELD, RACHAEL EVA handles 1 pending office action, while the other distinct examiner manages the remaining case.
Both pending actions are located within 1 distinct art unit, which suggests a degree of technical similarity between the applications. For the practitioner, this means that although there are 2 distinct examiners to satisfy, the overarching policy and technical standards of the 1 distinct art unit will apply to the applications. This can lead to a predictable prosecution environment.
The focus on Biotechnology & Pharmaceuticals indicates a commitment to a technical field. With 2 pending office actions, Mapkure LLC is actively engaging with the USPTO through 2 distinct examiners. BREDEFELD, RACHAEL EVA, by managing 1 pending office action, represents a portion of the current workload. The concentration in 1 distinct art unit allows for the potential reuse of technical arguments across both pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BREDEFELD, RACHAEL EVA | 1 | 27.4% | +35.0% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18487237 | COMBINATION FOR USE IN TREATING CANCERS | CORNET, JEAN P | 23d overdue |
| 18966838 | Methods of Treating Cancer With a B-RAF Inhibitor | BREDEFELD, RACHAEL EVA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18487237 | COMBINATION FOR USE IN TREATING CANCERS | CORNET, JEAN P | 23d overdue |
| 18966838 | Methods of Treating Cancer With a B-RAF Inhibitor | BREDEFELD, RACHAEL EVA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18966838 | Methods of Treating Cancer With a B-RAF Inhibitor | BREDEFELD, RACHAEL EVA | — | §103§112DP | Non-Final OA | — | Pending | Dec 03, 2024 |
| 18487237 | COMBINATION FOR USE IN TREATING CANCERS | CORNET, JEAN P | 1628 | §103§112Other | Final Rejection | 23d overdue | Pending | Oct 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial